Pharsight

1. List of Korlym drug patents

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
US10195214	May, 2019	FWD Entered	Corcept Therapeutics, Inc.	Teva Pharmaceuticals USA, Inc.
US8921348	August, 2018	FWD Entered	Corcept Therapeutics Inc.	Neptune Generics LLC

^new

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8921348	CORCEPT THERAP	Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists	Aug, 2028 (5 years from now)
US10842801	CORCEPT THERAP	Optimizing mifepristone absorption	Nov, 2032 (9 years from now)
US10500216	CORCEPT THERAP	Optimizing mifepristone absorption	Mar, 2033 (9 years from now)
US9943526	CORCEPT THERAP	Optimizing mifepristone levels for cushing's patients	Apr, 2036 (12 years from now)
US10166242	CORCEPT THERAP	Optimizing mifepristone levels for Cushing's patients	Apr, 2036 (12 years from now)
US10166243	CORCEPT THERAP	Optimizing mifepristone levels for cushing'S patients	Apr, 2036 (12 years from now)
US10660904	CORCEPT THERAP	Optimizing mifepristone levels for cushing's patients	Apr, 2036 (12 years from now)
US10495650	CORCEPT THERAP	Method for differentially diagnosing ACTH-dependent Cushing's syndrome	Aug, 2036 (13 years from now)
US10006924	CORCEPT THERAP	Method for differentially diagnosing ACTH-dependent cushing's syndrome	Aug, 2036 (13 years from now)
US9829495	CORCEPT THERAP	Method for differentially diagnosing ACTH-dependent Cushing's syndrome	Aug, 2036 (13 years from now)
US10151763	CORCEPT THERAP	Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome	Jan, 2037 (13 years from now)
US10195214	CORCEPT THERAP	Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors	Jun, 2037 (14 years from now)
US10842800	CORCEPT THERAP	Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors	Jun, 2037 (14 years from now)
US10314850	CORCEPT THERAP	Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients	Aug, 2038 (15 years from now)
US10780097	CORCEPT THERAP	Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients	Aug, 2038 (15 years from now)
US10231983	CORCEPT THERAP	Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients	Aug, 2038 (15 years from now)